Sleep induced by low doses of apomorphine in rats

Mereu, Giampaolo; Scarnati, Eugenio; Paglietti, E.; Quarantotti, B. Pellegrini; Chessa, P; Chiara, G. Di; Gessa, Gian Luigi

doi:10.1016/0013-4694(79)90071-3

Cited by 56 publications

(9 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the similar dose-dependent effects reported for apomor¬ phine underscore the role of dopaminergic transmis¬ sion in the regulation of sleep and wakefulness. 41 We hypothesize that sleep disruption in mildly to moderately affected patients with PD, as in our study, is caused by the dose-dependent effect of levodopa or do¬ pamine agonists on sleep regulation. In more severely affected patients, these drugs have a beneficial effect on nocturnal disabilities (eg, problems with turning over in bed, pain, and stiffness) of PD that cause sleep disrup¬ tion.…”

Section: Sleep Disruption In Pdmentioning

confidence: 50%

Sleep Disruption in Parkinson's Disease

Hilten¹

1994

Arch Neurol

146

View full text Add to dashboard Cite

Section: Sleep Disruption In Pdmentioning

confidence: 50%

Sleep Disruption in Parkinson's Disease

Hilten¹

1994

Arch Neurol

146

View full text Add to dashboard Cite

“…Animal studies suggest that penile erections, yawning, and sedation induced by low doses of Apo are centrally mediated behaviors sensitive to neuroleptic reversal (Baraldi et aL, 1977;Meren et aL, 1979). Therefore, since domperidone did not block the development of penile erections or, in keeping with Corsini el aL (1979), yawning, the blockade of Apo-dependent GH secretion probably involves an action outside the blood-brain barrier.…”

Section: Discussionmentioning

confidence: 85%

Effect of domperidone on apomorphine-induced growth hormone secretion in normal men

Lal

Nair

Iskandar

et al. 1982

J. Neural Transmission

View full text Add to dashboard Cite

Domperidone, a peripheral dopamine (DA) receptor blocker which poorly crosses the blood-brain barrier and which is inactive towards dopamine-sensitive adenylate cyclase, in a dose (100 micrograms/kg) sufficient to increase serum prolactin levels at least 5-fold, decreased the growth hormone (GH) response to the DA receptor agonist, apomorphine HCI (Apo) (0.5 gm s.c.) in each of six normal men examined. The mean GH increment at 30, 45, 60 and 75 min following Apo injection, the mean individual peak increment and the mean individual GH secretion (ng min) was significantly decreased by domperidone pretreatment (p less than 0.005 -p less than 0.002). These results indicate that in man Apo stimulates GH secretion by an effect on DA receptors which are not linked to adenylate cyclase and which are situated at a locus in the hypothalamic-pituitary axis that lies outside the blood-brain barrier.

show abstract

“…The facilitation of sleep occurrence caused by small doses of apomorphine is in accord with results obtained by others. Thus, Mereu et al (1979) found an increment of SWS and REMS in rats aftr SC doses of 0.025 and 0.050 mg/kg apomorphine. Cianchetti et al (1981) found that apomorphine given to man in nonemetic doses by continous IV infusion increased stage 2 sleep.…”

Section: Discussionmentioning

confidence: 98%

Biphasic effects of dopamine D-2 receptor agonists on sleep and wakefulness in the rat

et al. 1988

View full text Add to dashboard Cite

The effects of the dopamine (DA) receptor agonists apomorphine, bromocriptine and pergolide were compared with those produced by a DA receptor antagonist, haloperidol, in rats implanted with electrodes for chronic sleep recordings. Apomorphine (0.025-2.0 mg/kg) and bromocriptine (0.25-6.0 mg/kg) induced biphasic effects such that low doses decreased wakefulness (W) and increased slow wave sleep (SWS) and REM sleep (REMS), while large doses induced opposite effects. The effects of pergolide (0.05-0.5 mg/kg) on W and SWS were also biphasic, while REMS was suppressed over the range of dosages given. At 0.040 mg/kg, haloperidol increased W, while at 0.160 mg/kg it produced the opposite effect. Pretreatment with haloperidol (0.020 mg/kg) in a dose which preferentially acts at presynaptic sites reversed the effects of low doses of apomorphine, bromocriptine or pergolide on sleep and W. However, the compound differed substantially in its ability to block agonist effects. The increase in sleep after low doses of apomorphine, bromocriptine or pergolide could be related to activation of presynaptic D-2 receptors located on DA axons of mesolimbic and mesocortical systems. In addition, inhibition of norepinephrine and acetylcholine neurons having inhibitory D-2 receptors could contribute to the increase of sleep after small doses of the DA agonists.

show abstract

Sleep induced by low doses of apomorphine in rats

Cited by 56 publications

References 12 publications

Sleep Disruption in Parkinson's Disease

Sleep Disruption in Parkinson's Disease

Effect of domperidone on apomorphine-induced growth hormone secretion in normal men

Biphasic effects of dopamine D-2 receptor agonists on sleep and wakefulness in the rat

Contact Info

Product

Resources

About